Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.43 |
| ▸ | ACVR1B | P36896 | 12/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22270341 | 0.83 | TGFBR1 (0.44) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16879672 | 0.82 | TGFBR1 (0.66) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL21177797 | 0.82 | TGFBR1 (0.46) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL21177487 | 0.81 | TGFBR1 (0.44) | TGFBR1TGFBR2CSNK1DMAPK11MAPK14 | |
| SCHEMBL16879863 | 0.71 | TGFBR1 (0.73) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL16879247 | 0.71 | TGFBR1 (0.73) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL858107 | 0.70 | TTBK1 (0.51) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL21177441 | 0.68 | TGFBR1 (0.45) | TGFBR1BMPR1ATGFBR2CSNK1DMAPK11 | |
| SCHEMBL16879588 | 0.68 | TDO2 (0.40) | MAPK14ROCK1 | |
| SCHEMBL16879809 | 0.67 | TGFBR1 (0.56) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-06-04 | — | — | US | disclosed |
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-06-04 | — | — | US | disclosed |
| WO-2019142128-A1 | DUAL INHIBITORS OF ALK5 AND P38Α MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019142128-A1 | DUAL INHIBITORS OF ALK5 AND P38Α MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | MAP2K2, MAP2K5, MAP2K1 | TGFBR1 27/4885ACVR1B 61/4885ACVRL1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.